Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amitriptyline + pregabalin
- Development stage
- Unknown
- Lead developer
- Health N U Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AmNurite P is an oral fixed-dose combination therapy developed by Health N U Therapeutics, consisting of the tricyclic antidepressant amitriptyline hydrochloride and the gabapentinoid pregabalin in a sustained-release (SR) formulation. This combination is primarily indicated for the management of neuropathic pain, such as diabetic peripheral neuropathy and postherpetic neuralgia. Amitriptyline acts by inhibiting the reuptake of serotonin and norepinephrine in the synaptic cleft, thereby enhancing descending inhibitory pain pathways. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters like glutamate and substance P. Together, these agents provide synergistic analgesic effects for chronic pain conditions, with the sustained-release formulation of pregabalin allowing for optimized dosing schedules.
- Brand names
- AmNurite P
- Other names
- Amitriptyline HCl and Pregabalin SR TabletsAmitriptyline hydrochloride and Pregabalin sustained release tablets
02
Targets
HTR2A (Serotonin receptor 5-HT2A)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)HTR6 (5-hydroxytryptamine receptor 6)HTR7 (5-hydroxytryptamine receptor 7)Nicotinic Acetylcholine ReceptorNET (Norepinephrine Transporter)HTR2C (5-hydroxytryptamine 2C receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on amitriptyline + pregabalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amitriptyline + pregabalin.